orforglipron

01/01/2023 - "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study."
01/01/2023 - "We assessed the efficacy and safety of orforglipron versus placebo or dulaglutide in participants with type 2 diabetes. "
12/01/2023 - "Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials."
12/01/2023 - "The present systematic review aimed to synthesize available data from recently published randomized trials (RCTs) investigating the efficacy and safety of the novel, orally administered, small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs) orforglipron and danuglipron for the treatment of type 2 diabetes mellitus (T2DM), obesity or both. "
01/01/2023 - "Orforglipron, an oral, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist, is in development for type 2 diabetes and obesity. "

10/01/2023 - "Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. "
09/07/2023 - "Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity."
12/01/2023 - "Preliminary evidence supports that orforglipron and danuglipron are efficient in glycemic control and weight reduction in T2DM, obesity or both. "
10/01/2023 - "In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk."
12/01/2023 - "Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials."

09/07/2023 - "A weight reduction of at least 10% by week 36 occurred in 46 to 75% of the participants who received orforglipron, as compared with 9% who received placebo. "
09/07/2023 - "Daily oral orforglipron, a nonpeptide GLP-1 receptor agonist, was associated with weight reduction. "
12/01/2023 - "Preliminary evidence supports that orforglipron and danuglipron are efficient in glycemic control and weight reduction in T2DM, obesity or both. "
10/01/2023 - "In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk."
09/07/2023 - "Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity. "

09/07/2023 - "At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. "
01/01/2023 - "Substantial reductions in body weight of up to 5.4 kg were observed after 4 weeks in orforglipron-treated participants, compared to a reduction of 2.4 kg with placebo (P < 0.05). "
01/01/2023 - "Orforglipron treatment resulted in meaningful reductions in HbA1c and body weight, with an adverse event profile consistent with that of other GLP-1RAs. "
01/01/2023 - "In the placebo and orforglipron groups, respectively, baseline HbA1c was 8.1% and 8.0%, and baseline body weight was 90.3 and 88.4 kg. "

10/01/2023 - "In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk."